|
1
|
Martelli M, Ferreri AJM, Agostinelli C, Di
Rocco A, Pfreundschuh M and Pileri SA: Diffuse large B-cell
lymphoma. Crit Rev Oncol Hematol. 87:146–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wright GW, Huang DW, Phelan JD, Coulibaly
ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, et
al: A probabilistic classification tool for genetic subtypes of
diffuse large B cell lymphoma with therapeutic implications. Cancer
Cell. 37:551–568.e14. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hertzberg M: R-CHOP in DLBCL: Priming for
success. Blood. 139:1121–1122. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang L and Li LR: R-CHOP resistance in
diffuse large B-cell lymphoma: Biological and molecular mechanisms.
Chin Med J (Engl). 134:253–260. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldfinger M and Cooper DL: Refractory
DLBCL: Challenges and treatment. Clin Lymphoma Myeloma Leuk.
22:140–148. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Y and Barta SK: Diffuse large B-cell
lymphoma: 2019 Update on diagnosis, risk stratification, and
treatment. Am J Hematol. 94:604–616. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li T, Yu J, Hou M, Zha S, Cheng Q, Zheng Q
and Li L: Quantitative evaluation of therapy options for
relapsed/refractory diffuse large B-cell lymphoma: A model-based
meta-analysis. Pharmacol Res. 187:1065922023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He MY and Kridel R: Treatment resistance
in diffuse large B-cell lymphoma. Leukemia. 35:2151–2165. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoy SM: Sintilimab: First global approval.
Drugs. 79:341–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X and Yi Y: Recent updates on
sintilimab in solid tumor immunotherapy. Biomark Res. 8:692020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li
Q, Lu Y, Chen Y, Guo Y, et al: Sintilimab plus a bevacizumab
biosimilar (IBI305) versus sorafenib in unresectable hepatocellular
carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study.
Lancet Oncol. 22:977–990. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen C, Zhang W, Zhou D and Zhang Y:
Sintilimab and chidamide for refractory transformed diffuse large B
cell lymphoma: A case report and a literature review. Front Oncol.
11:7574032021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roach C, Zhang N, Corigliano E, Jansson M,
Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D and
Kulangara K: Development of a companion diagnostic PD-L1
immunohistochemistry assay for pembrolizumab therapy in
non-small-cell lung cancer. Appl Immunohistochem Mol Morphol.
24:392–397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
National Comprehensive Cancer Network.
NCCN clinical practice guidelines in oncology, . B-cell lymphomas.
Version 4.2019. 2019.Retrieved from. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
|
|
16
|
Tanimura A, Nakazato A and Tanaka N: MYD88
signals induce tumour-initiating cell generation through the
NF-κB-HIF-1α activation cascade. Sci Rep. 11:39912021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chapuy B, Stewart C, Dunford AJ, Kim J,
Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et
al: Molecular subtypes of diffuse large B cell lymphoma are
associated with distinct pathogenic mechanisms and outcomes. Nat
Med. 24:679–690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cohen JB, Shah NN, Alencar AJ, Gerson JN,
Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, Fenske T, et al:
MCL-133 pirtobrutinib, a highly selective, non-covalent
(reversible) BTK inhibitor in previously treated mantle cell
lymphoma: Updated results from the phase 1/2 BRUIN study. Clin
Lymph Myelom Leuk. 22 (Suppl 2):S394–S395. 2022. View Article : Google Scholar
|
|
19
|
Georgiou K, Chen L, Berglund M, Ren W, de
Miranda NF, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K, et al:
Genetic basis of PD-L1 overexpression in diffuse large B-cell
lymphomas. Blood. 127:3026–3034. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Green MR, Monti S, Rodig SJ, Juszczynski
P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub
TR, et al: Integrative analysis reveals selective 9p24.1
amplification, increased PD-1 ligand expression, and further
induction via JAK2 in nodular sclerosing Hodgkin lymphoma and
primary mediastinal large B-cell lymphoma. Blood. 116:3268–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Godfrey J, Tumuluru S, Bao R, Leukam M,
Venkataraman G, Phillip J, Fitzpatrick C, McElherne J, MacNabb BW,
Orlowski R, et al: PD-L1 gene alterations identify a subset of
diffuse large B-cell lymphoma harboring a T-cell-inflamed
phenotype. Blood. 133:2279–2290. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang T, Liu H, Jiao L, Zhang Z, He J, Li
L, Qiu L, Qian Z, Zhou S, Gong W, et al: Genetic characteristics
involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the
immunosuppressive microenvironment in DLBCL. J Immunother Cancer.
10:e0041142022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang L, Mai W, Jiang W and Geng Q:
Sintilimab: A promising anti-tumor PD-1 antibody. Front Oncol.
10:5945582020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lesokhin AM, Ansell SM, Armand P, Scott
EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ,
Lebovic D, et al: Nivolumab in patients with relapsed or refractory
hematologic malignancy: Preliminary results of a phase Ib study. J
Clin Oncol. 34:2698–2704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ansell SM, Minnema MC, Johnson P,
Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM,
Reddy N, et al: Nivolumab for relapsed/refractory diffuse large
B-cell lymphoma in patients ineligible for or having failed
autologous transplantation: A single-arm, phase II study. J Clin
Oncol. 37:481–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gregory GP, Kumar S, Wang D, Mahadevan D,
Walker P, Wagner-Johnston N, Escobar C, Bannerji R, Bhutani D,
Chang J, et al: Pembrolizumab plus dinaciclib in patients with
hematologic malignancies: The phase 1b KEYNOTE-155 study. Blood
Adv. 6:1232–1242. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang M, Fowler N, Wagner-Bartak N, Feng L,
Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, et
al: Oral lenalidomide with rituximab in relapsed or refractory
diffuse large cell, follicular and transformed lymphoma: A phase II
clinical trial. Leukemia. 27:1902–1909. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Messal N, Serriari NE, Pastor S, Nunès JA
and Olive D: PD-L2 is expressed on activated human T cells and
regulates their function. Mol Immunol. 48:2214–2219. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yearley JH, Gibson C, Yu N, Moon C, Murphy
E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, et al: PD-L2
expression in human tumors: Relevance to Anti-PD-1 therapy in
cancer. Clin Cancer Res. 23:3158–3167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lohr JG, Stojanov P, Lawrence MS, Auclair
D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW,
Slager SL, et al: Discovery and prioritization of somatic mutations
in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
Proc Natl Acad Sci USA. 109:3879–3884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lohmann K and Klein C: Next generation
sequencing and the future of genetic diagnosis. Neurotherapeutics.
11:699–707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mosele F, Remon J, Mateo J, Westphalen CB,
Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M,
Meric-Bernstam F, et al: Recommendations for the use of
next-generation sequencing (NGS) for patients with metastatic
cancers: A report from the ESMO precision medicine working group.
Ann Oncol. 31:1491–1505. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hussen BM, Abdullah ST, Salihi A, Sabir
DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M and
Jamali E: The emerging roles of NGS in clinical oncology and
personalized medicine. Pathol Res Pract. 230:1537602022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Adams E, Sepich-Poore GD,
Miller-Montgomery S and Knight R: Using all our genomes:
Blood-based liquid biopsies for the early detection of cancer. View
(Beijing). 3:202001182022.PubMed/NCBI
|
|
36
|
Huang Y, Du S, Liu J, Huang W, Liu W,
Zhang M, Li N, Wang R, Wu J, Chen W, et al: Diagnosis and prognosis
of breast cancer by high-performance serum metabolic fingerprints.
Proc Natl Acad Sci USA. 119:e21222451192022. View Article : Google Scholar : PubMed/NCBI
|
